Several types of mTOR inhibitors, the first- and second-generation, have been examined in various cancer models, including breast, lung, gastric, colorectal, prostate, head and neck, lymphoma, urinary bladder, renal, and melanoma (Zou et al. 2020; Li et al. 2018). Here, MTOR is linked to melanoma.